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Frequently, patients with hepatitis C virus (HCV) chronic infection have high levels of serum anti-thyroperoxidase and/or anti-
thyroglobulin autoantibodies, ultrasonographic signs of chronic autoimmune thyroiditis, and subclinical hypothyroidism, in female
gender versus healthy controls, or hepatitis B virus infected patients. In patients with “HCV-associated mixed cryoglobulinemia”
(MC + HCV), a higher prevalence of thyroid autoimmune disorders was shown not only compared to controls, but also versus
HCV patients without cryoglobulinemia. Patients withMC+HCV orHCV chronic infection show a higher prevalence of papillary
thyroid cancer than controls, in particular in patients with autoimmune thyroiditis. Patients with HCV chronic infection, or with
MC +HCV, in presence of autoimmune thyroiditis, show higher serum levels of T-helper (Th)1 (C-X-Cmotif) ligand 10 (CXCL10)
chemokine, but normal levels of Th2 (C-C motif) ligand 2 chemokine, than patients without thyroiditis. HCV thyroid infection
could act by upregulating CXCL10 gene expression and secretion in thyrocytes recruitingTh1 lymphocytes that secrete interferon-
𝛾 and tumor necrosis factor-𝛼. These cytokines might induce a further CXCL10 secretion by thyrocytes, thus perpetuating the
immune cascade, whichmay lead to the appearance of autoimmune thyroid disorders in genetically predisposed subjects. A careful
monitoring of thyroid function, particularly where nodules occur, is recommended in HCV patients.
1. Introduction
About 130–170 million people worldwide have been infected
by hepatitis C virus (HCV) [1]. Hepatocytes represent the
major site of viral replication, and the replication of HCV is
present in extrahepatic tissues and peripheral bloodmononu-
clear cells [2].
Previous studies have shown that 38–76% of patients
with chronic HCV infection develop at least one extrahepatic
manifestation (EHM) [3, 4].
An association between HCV and mixed cryoglobuline-
mia (MC) was first described; subsequently, the involvement
of many organs and systems was reported (kidney, skin,
eyes, joints, and nervous system). The infected extrahepatic
tissues might act as a reservoir for HCV [5] and play a
role in both HCV persistence and reactivation of infection.
HCV, as an etiological agent replicating and expressing viral
proteins in extrahepatic tissues itself, contributes to EHM
associated with chronicHCV infection. An important feature
of HCV is that the virus avoids immune elimination; a
consequence is chronic infection and an accumulation of
circulating immunocomplexes and autoimmune phenomena
[6–8], as recently Cheng et al. have demonstrated in their
study among 297 Chinese patients [9].
These EHM mainly include autoimmune disorders [10–
12] such as MC [13, 14] and Sjogren’s syndrome and
endocrinological diseases as autoimmune thyroid disorders
(AITD) and type 2 diabetes [15–17].
2. Autoimmune Thyroiditis
Hashimoto’s thyroiditis or autoimmune chronic thyroiditis
(AT) is among the most common thyroid diseases. AT is
the most widespread thyroiditis form and its prevalence is
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definitely more frequent in female gender and in the elderly.
The incidence in female gender is of 3,5 cases/1000 subjects
per year, while in men it is lower (0,8 cases/1000 persons per
year): there is a remarkable variability in different geographic
areas [18].
AT is an organ-specific autoimmune disease, morpholog-
ically characterized by a chronic lymphocytes infiltration of
thyroid and the presence of circulating autoantibodies such
as antiperoxidase (AbTPO) and antithyroglobulin (AbTg).
The inflammatory process leads to a follicular destruction;
indeed, AT is the most common cause of hypothyroidism in
areas of iodine sufficiency [19].
Occasionally, thyroid stimulating hormone (TSH) recep-
tor blocking antibodies can be responsible of an atrophic
form of AT; more rarely, anti-TSH receptor stimulating
antibodies can cause a transient form of hyperthyroidism
(hashitoxicosis) [20].
Risk factors associated with AT are numerous [21–24].
(a) Age: the prevalence of disease tends to increase with
age.
(b) Genetic: a significant association between
Hashimoto’s thyroiditis and some histocompatibility
antigens (HLA-DR, HLA-DR5, and some DQ alleles)
is demonstrated. Many other susceptibility genes
have been associated with AT; for example, specific
CTLA4 gene polymorphisms are linked to a possible
development of antithyroid antibodies [25].
(c) Iodine: an increased AT prevalence is observed in
areas of iodine sufficiency, compared with iodine-
deficient areas [26, 27].
(d) Selenium: a selenium deficit is linked to a higher AT
prevalence [28].
(e) Irradiation: AT occurs more frequently after the
exposure to low doses of radiations [26].
(f) Cytokine: the treatment with Interferon- (IFN-) 𝛼, or
with Interleukin- (IL-) 2, can promote the onset of AT
in predisposed patients [29].
(g) Infections: it was seen that several viral infections can
predispose to an AT in animals. Moreover, different
studies tried to associate AT with viral infections in
humans with conflicting results [30–33].
3. Chronic HCV (CHC) Infection and Thyroid
3.1. CHC Infection and Thyroid Autoimmunity. In a first
study, Tran et al. report two cases of Hashimoto’s thyroiditis
associatedwith chronic activeHCV infection, suggesting that
HCV infection might be involved in the appearance of AT
[34, 35].
The prevalence of HCV infection in patients with differ-
ent thyroid disorders has been evaluated by several studies
with conflicting results. Duclos-Valle´e et al. evaluated the
prevalence of HCV infection in 200 patients with thyroid
diseases; among 50 patients with simple goiter, none were
anti-HCV-positive; among 50 individuals with goiter, 2 were
positive; among 5 individuals with myxedema, 2 were posi-
tive; among 50 patients with Hashimoto’s thyroiditis, 12 were
positive.These results suggested that HCV infectionmight be
associated with AT [36]. Recently, Yang et al. compared 462
persons with positive AbTPO and/or AbTg to 360 persons
with antibody negativity and no difference in the prevalence
of anti-HCV positivity between the 2 groups (1.3% versus
0.53%; 𝑃 > 0.05) was found [37]. In a study conducted
by Marconcini et al., 66 HCV+ patients were evaluated and
AbTPOswere detected in 4/54 (7.4%) of the patients, whereas
AbTgs were detected in none of the patients (0/48) [38].
Conflicting results have been reported from earlier stud-
ies of patients with CHC, with some supporting an associ-
ation of HCV infection with AITD [39–47] and others not
[48, 49].
However, some of the earlier studies were negative
because of the lack of control for factors which may affect the
development of thyroid autoimmunity, such as iodine intake
[50].
Indeed, the largest study about HCV and thyroiditis,
in which iodine deficiency was evaluated, demonstrated
that both hypothyroidism and thyroid autoimmunity were
significantly more common in patients with HCV compared
to controls [41].
The prevalence of thyroid disorders in 630 consecutive
patients with chronic hepatitis due to HCV infection was
investigated; all patients were free of cirrhosis and hepa-
tocarcinoma and were not on interferon treatment. Three
control groups were included: (a) 389 subjects from an
iodine-deficient area, (b) 268 persons living in an area of
iodine sufficiency, and (c) 86 patients > 40 years of age with
chronic hepatitis B. Levels of thyroid-stimulating hormone
(TSH), free T4 (FT4), and free T3 (FT3), as well as AbTgs
and AbTPOs, were measured. Mean TSH levels were higher
(𝑃 = 0.001) and FT3 and FT4 levels were lower (𝑃 < 0.0001)
in patients with CHC than in all other groups. Patients
with CHC were more likely to have hypothyroidism (13%
(𝑛 = 82)), AbTgs (17% (𝑛 = 108)), and AbTPOs (21%
(𝑛 = 132)) than were any of the other groups. The results of
this study suggested that both hypothyroidism and thyroid
autoimmunity are more common in patients with CHC,
even in the absence of cirrhosis, hepatocellular carcinoma,
or interferon treatment, than in HCV-negative controls or in
patients with chronic hepatitis B infection [41].
Evidence for this association also came from a study
that reported a higher prevalence of hypothyroidism and
AbTgs in untreated children with CHC compared to healthy
non-HCV infected controls [51]. In most studies, examining
the frequency of thyroid disorders in patients with HCV,
approximately 10–15% of the patients had positive thyroid
antibodies before the beginning of the therapy with IFN [52–
58]. Moreover, pooling of data from controlled studies on
HCV infection and thyroid autoimmunity demonstrated a
significant increase in the risk of thyroiditis in HCV patients
[59]. A large study which included 146394 patients infected
with HCV confirmed these results showing a significant
increased risk for thyroiditis [60]. This was a retrospective
cohort study of users of US Veterans Affairs health care facil-
ities from 1997 to 2004, which included 146394 CHC patients
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who had at least 2 visits and 572293 patients uninfected with
HCV.The thyroiditis risk was significantly increased in HCV
patients. Since 97% of HCV patients were men and it is well
known that male gender has a lower risk of thyroiditis than
female, this result is particularly interesting [60].
The presence of higher risk of AT in female gender
increased circulating levels of AbTPOs and increased risk of
hypothyroidism in female gender and AbTPO-positive sub-
jects characterized the pattern of thyroid disorders observed
in HCV infection [59, 61, 62].
Despite their remarkable therapeutic efficacy, IFN-𝛼
adverse effects are well-known, from influenza-like symp-
toms to hematologic effects, neuropsychiatric symptoms,
and thyroid diseases [63]. In particular, previous studies
showed that female gender is one of the most common
risk factors that predict the development of AITD during
interferon therapy [64, 65]. An association between IFN-𝛼
and thyroid disease was recognized as early as 1985 in patients
who have been treated with IFN-𝛼 for breast cancer [66].
Later, several cases have reported the possible association
between thyroid disease and IFN-𝛼 [67]. Different forms
of IFN induced thyroid autoimmunity have been identified,
such as GD, thyroiditis, and subclinical hypothyroidism [68].
Graves’ hyperthyroidism is the less common type, because
only 20–25% of all patients with IFN-related thyrotoxicosis
are linked to Graves’ disease (GD) induced by circulating
thyroid receptor antibodies (TRAb) [69, 70].
Interferon induced thyroiditis (IIT) can be divided into
two main groups: autoimmune type and nonautoimmune
type [71]. The former can manifest as HT and GD and
sometimes may be related to the production of thyroid
autoantibodies without clinical disease.
Another interesting classification of interferon induced
hyperthyroidism has been proposed by Czarnywojtek et al.
[72] (in comparison with amiodarone induced thyrotoxicosis
(AIT)): (I) type 1, corresponding to type I amiodarone
induced thyrotoxicosis (AIT): (a) GT without TAO and
(b) GT with TAO (mild or severe); (II) type 2 destructive
thyrotoxicosis, partially analogous to type II AIT: (a) asymp-
tomatic: silent thyroiditis and (b) symptomatic; and (III)
type 3 unknown aetiology, partial analogy to type III AIT—
undefined or mixed.
The presence of thyroid autoantibodies before the initi-
ation of IFN-𝛼 therapy is an important risk factor for the
development of IIT. In HCV-positive individuals, the pro-
gression toward hypothyroidism, in thyroid autoantibodies
positive patients who undergo IFN-𝛼 treatment, is often asso-
ciated with an increase in antibody titers [73]. Furthermore,
Prummel and Laurberg showed that positive pretreatment
AbTPOs are an important risk factor for the development
of thyroid dysfunction [74]. There is also an obvious link
between female sex, old age, and genetic predisposition with
the development of antibodies [75, 76].
3.2. Cryoglobulinemia and Thyroid Diseases. Few anecdotal
studies evaluated AITD in patients with cryoglobulinemia
[77, 78].
A case-control prospective study has been conducted
to evaluate thyroid disorders in 93 MC + HCV patients,
matched by sex and age (±2 years), to 93 patients with
CHC without MC and 93 healthy (HCV-negative) controls
from the local population [79, 80]. The following thyroid
autoimmune abnormalities were significantly more frequent
inMC+HCVpatients than inHCV-negative controls: serum
AbTPO levels (28% versus 9%), serum AbTPO and/or AbTg
levels (31% versus 12%), AT (35% versus 16%), and subclinical
hypothyroidism (11% versus 2%). Serum AbTPOs were also
significantly more frequent in MC + HCV patients than in
CHC controls (28% versus 14%). A higher prevalence of
thyroid disorders in patients with MC + HCV not only with
respect to controls, but also with respect to HCV patients
without cryoglobulinemia was shown, suggesting a careful
monitoring of thyroid function in these patients [80].
The presence of a higher risk of AT and hypothyroidism
and increased circulating levels of AbTPO, in female gender,
characterized the pattern of thyroid disorders observed in
MC +HCV infection, similarly to HCV patients without MC
[59, 61].
3.3. CHC Infection and Thyroid Cancer. A high prevalence
of papillary thyroid cancer (PTC) was first observed in 139
HCV patients (2.2%), while no case was observed in 835
control subjects who were long-term residents of an iodine-
deficient area [81], and it was subsequently confirmed in
other studies [82, 83]. Montella et al. have carried out a case-
controlled study on the different oncological pathologies.
They screened 495 patients with different types of cancer:
114 cases of liver cancer, 41 of multiple myeloma, 111 of non-
Hodgkin’s lymphomas, 130 of thyroid cancers, and 63 cases
of Hodgkin’s disease. The controls were 226 patients with no
history of cancer. The relationship between each cancer and
HCV infectionwas assessed bymeans of odds ratios (OR) and
corresponding 95% confidence intervals.
Risks were greater for liver cancer (OR = 32.9, 95%
CI 16.5–65.4, 𝑃 < 0.0001), multiple myeloma (OR = 4.5,
95% CI 1.9–10.7, 𝑃 = 0.0004), and B-cell non-Hodgkin’s
lymphoma (OR = 3.7, 95% CI 1.9–7.4, 𝑃 = 0.0001). For
Hodgkin’s disease, there was no significant association (𝑃 =
0.3). An association between HCV and thyroid cancer was
noted (OR = 2.8, 95% CI 1.2–6.3, 𝑃 = 0.01) [83].
The prevalence of thyroid cancer was also investigated in
a series of unselected 94 MC + HCV patients in comparison
with a gender- and age-matched control group obtained
from a sample of the general population (470 subjects).
The prevalence of thyroid nodules was higher in control
subjects than in MC + HCV patients (65.3% versus 54.8%),
even though not significantly. Two patients with PTC were
found in the MC + HCV series, while no case was observed
among controls (𝑃 = 0.001). Lymphocytic infiltration was
observed in the thyroid tissue in both MC + HCV patients
with PTC [84]. Other studies have confirmed an association
betweenAT and thyroid cancer [85, 86]. Accordingly, features
of AT were observed more frequently in HCV patients
than in controls suggesting that AT may be a predisposing
condition for thyroid cancer [87]. Since about 15–30% of
HCV patients may show an aggressive disease, for example,
lung metastases, difficult to treat [88, 89], the finding of an
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increased prevalence of thyroid cancer in these patients is
clinically relevant [90].
3.4. Immunopathogenesis of HCV Infection and AITD. Sev-
eral molecular mechanisms have been suggested for the
association of CHC with AT: (a) molecular mimicry or
cross-reactivity which may occur between viral antigens and
thyroidal antigens [91], (b) heat shock proteins expression in
thyroid gland [92], and (c) abnormal expression ofMHCclass
II molecules by thyrocytes [93].
An increased expression of IFN-𝛾 and IFN-𝛾 inducible
chemokines [94, 95], in particular (C-X-C motif) ligand 10
chemokine (CXCL10), has been shown in hepatocytes and
in lymphocytes of HCV infected patients, directly related to
the degree of inflammation and to an increase in circulating
levels of IFN-𝛾 and CXCL10 [40, 96–103]. CXCL10 is one
of chemokines with C-X-C motif. IP-10 activates specifically
CXCR3 receptor that is a G protein-coupled receptor with
seven transmembrane domains mainly expressed in T acti-
vated lymphocytes, natural-killer cells (NKs), macrophages,
and B cells [104, 105]. Recent studies showed that CXCL10
expression in serum and/or tissue levels is increased in
autoimmune organ-specific diseases [106], such as type 1
diabetes [107–109], or systemic rheumatological diseases like
rheumatoid arthritis, systemic lupus erythematosus, systemic
sclerosis [97, 110], sarcoidosis [111, 112], and psoriatic arthritis
[113, 114].
High levels of CXCL10 are present in patients with AT, in
particular in the presence of hypothyroidism, and an involve-
ment of T-helper (Th)1 immune response in the induction of
AT [97, 115–117], GD, and Graves’ ophthalmopathy [97–100,
118] has been demonstrated, suggesting that intrathyroidal
lymphocytes and/or thyrocytes may be the source of CXCL10
[119]. Furthermore, the presence of HCV in the thyroid of
chronically infected patients has been recently shown [120,
121].
On the abovementioned bases, it has been speculated that
HCV thyroid infectionmay act by upregulatingCXCL10 gene
expression and secretion in thyrocytes recruiting Th1 lym-
phocytes that secrete IFN-𝛾 and tumor necrosis factor- (TNF-
) 𝛼. These cytokines induce CXCL10 secretion by thyrocytes,
thus perpetuating the immune cascade, whichmay lead to the
appearance of AITD in genetically predisposed subjects [111]
(Figure 1).
Recently, the finding of high serum levels of CXCL10
but normal levels of the prototype Th2 chemokine (C-C
motif) ligand 2 (CCL2) in MC + HCV patients with AT, in
comparison with patients without thyroiditis, has confirmed
this hypothesis. These data suggest that the Th1 CXCL10
chemokine is specifically linked to the appearance of AT in
these patients [122].
Serums CXCL10 and CCL2 were assayed in 60 MC +
HCV patients, in 45 patients with “MC with AT” (MC +
AT), and in controls (60 without (control 1) and 45 with AT
(control 2)). CXCL10 was significantly higher in control 2
than in control 1 (𝑃 < 0.001), in MC than in control 1, and
in MC + AT than in controls 1 and 2 and MC (𝑃 = 0.002).
A high CXCL10 level (>mean ± SD control 1; >167 pg/mL)
was present in 7% of control 1, 21% of control 2, 49% of MC,
HCV
secretion
Th1 lymphocytes
CXCL10 induces 
Th1 lymphocytes
Stimulation of
CXCL10 
secretion
IFN-𝛾
TNF-𝛼
+ CXCL10
Hep
atoc
ytes Thyrocytes
recruitment
Figure 1: HCV thyroid infection may act by upregulating CXCL10
gene expression and secretion in thyrocytes recruitingTh1 lympho-
cytes that secrete IFN-𝛾 andTNF-𝛼.These cytokines induceCXCL10
secretion by thyrocytes, thus perpetuating the immune cascade.
and 78% of MC + AT (𝑃 < 0.0001). CCL2 was significantly
higher in MC and in MC + AT than in control 1 or in control
2 (𝑃 < 0.01). A high CCL2 level (>mean ± SD control 1;
>730 pg/mL) was present in 2% of control 1, 1% of control 2,
18% MC, and 21% of MC + AT (𝑃 < 0.0001) [122].
Among the proinflammatory cytokines, IL-1𝛽 and TNF-
𝛼 were not associated with the presence of AT in MC + HCV
patients, while IL-6 was modestly but significantly increased
in patients with AT [5, 123–125].
On the whole, in agreement with what was observed in
other autoimmune disorders [126–129], the above reported
data underline the importance of the activation of the Th1
immunity in the initiation of AT in patients with MC +HCV.
4. Conclusion
In conclusion, the abovementioned results show a high preva-
lence of AITD in patients with CHC infection. The presence
of a higher risk of AT in female gender, increased circulating
levels of AbTPOs, and increased risk of hypothyroidism in
female gender and AbTPO-positive subjects characterized
the pattern of thyroid disorders observed in HCV infection.
In HCV patients with thyroid cancer, thyroidectomy is
required and, if appropriate, radioiodine treatment. Patients
with HCV infection with AITD where nodules occurred and
in fine needle aspiration biopsy without neoplastic processes
do require careful observation.
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